Tumour necrosis factor antagonists: structure, function, and tuberculosis risks (Q37298854)

19 August 2017

1 reference

title

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks (English)

1 reference

19 August 2017

0 references

0 references

Robert S Wallis

1

1 reference

19 August 2017

1 October 2008

1 reference

Lancet Infectious Diseases

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

10

1 reference

19 August 2017

601-611

1 reference

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Tumor necrosis factor signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Signal transduction by tumor necrosis factor and its relatives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Biological functions of tumor necrosis factor cytokines and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor alpha p55 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Differential effects of TNF and LTalpha in the host defense against M. bovis BCG

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Membrane tumor necrosis factor confers partial protection to Listeria infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Effectiveness of infliximab in treating selected patients with sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

European survey of BCG vaccination policies and surveillance in children, 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Here today--gone tomorrow: the case for transient acute tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Antirheumatic drugs and the risk of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Using automated pharmacy records to assess the management of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

The pharmacokinetics of etanercept in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Mechanisms of action of etanercept in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

INFLIXIMAB DOWNREGULATES INTERFERON-γ PRODUCTION IN ACTIVATED GUT T-LYMPHOCYTES FROM PATIENTS WITH CROHN'S DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Estimation of the annual risk of tuberculosis infection for white men in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Bacille Calmette-Guérin immunization in normal healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Comparative genomics of BCG vaccines by whole-genome DNA microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Risk of tuberculosis infection and tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Infliximab for rheumatoid arthritis in a patient with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Reconsidering adjuvant immunotherapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970227-5

7 January 2021

10.1016/S1473-3099(08)70227-5

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18922482